Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid Leukemia

ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABLT315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that “switch-control” inhibitors block BCR-ABLT315I activity by preventing ABL from switching from the inactive to active conformation.